無料セミナー : 2019年11月19日『手術用ロボット:外科医療におけるトランスフォーメーション』 BIS Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Digital Landscape:2型糖尿病

Digital Landscape: Type 2 Diabetes

発行 GlobalData 商品コード 692903
出版日 ページ情報 英文 142 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.25円で換算しております。
Back to Top
Digital Landscape:2型糖尿病 Digital Landscape: Type 2 Diabetes
出版日: 2018年08月27日 ページ情報: 英文 142 Pages
概要

当レポートでは、米国およびEUCAN諸国(EU5カ国・カナダ)の製薬企業がデジタル環境(ブランドウェブサイト、非ブランド/疾患啓発ウェブサイト、モバイルアプリ、ソーシャルメディア)で2型糖尿病患者および医療従事者を対象に展開している取り組みについて詳細に調査し、主要企業の動向の比較、ウェブサイトアクセス数やアプリダウンロード数などのデータ分析、新たなキャンペーン活動の機会の特定、デジタルヘルスを形作るトレンドの評価、患者および医師のオンライン利用実態などについてまとめています。

対象医薬品

DPP-4阻害薬、SGLT2阻害薬、GLP-1受容体作動薬

対象企業

AbbVie、Novartis、Celgene、Janssen、Amgen、MSD、Merck、UCB、BMS、Pfizer、Eli Lilly、Sandoz、Mylan

目次

  • エグゼクティブサマリー
  • 近年の動向
  • 情勢と分析
  • 米国:2型糖尿病患者を対象とした取り組み
  • 米国:医療従事者を対象とした取り組み
  • EUCAN諸国:2型糖尿病患者を対象とした取り組み
  • EUCAN諸国:医療従事者を対象とした取り組み
  • 調査手法
目次
Product Code: GDHC039SP

"Digital Landscape: Type 2 Diabetes", analyzes digital activities undertaken by pharmaindustry in support of therapies for Type 2 Diabetes (T2D).

  • The report includes digital activities directed towards patients and/or HCPs
  • The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain)
  • The main focus of the report is DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists

Key Highlights

  • US Patients: Good support for US T2D patients across channels, particularly from Novo Nordisk, Merck, BI / Lilly and AstraZeneca. Updates seen in the branded space in 2017, with activity detected in the T2D / CV unbranded space from Novo Nordisk and BI / Lilly. Overall lack of diabetes-specific mobile apps from pharma, however Novo Nordisk and Roche were active in 2017. Increasing number of partnerships between pharma and technology companies could lead to future innovation in diabetes management.
  • US HCPs: Limited support for US HCPs beyond brand sites, with activity seen from many companies across the branded landscape in 2017. J&J provides the best unbranded and social media support to HCPs. Pharma-sponsored mobile app support is limited, with a number of companies sponsoring non-pharma offerings, including AstraZeneca and BI / Lilly. Novo Nordisk entered the HCP mobile app space in late 2017.
  • EUCAN Patients: Lilly provides strong branded support for Trulicity patients across Europe with multi-country, local-language sites and a mobile app. Sanofi has the most unbranded sites across EUCAN, and has the strongest examples of social media support in Canada. No pharma-sponsored social media accounts detected in Germany or the UK.
  • EUCAN HCPs: Sparse digital landscape for EUCAN HCPs. Lilly and Sanofi have brand content on corporate diabetes sites in Germany and the UK. Few HCP-directed unbranded sites were detected from pharma, with Sanofi's offering in France providing the best support features. Limited social media activity beyond corporate accounts, and all pharma-sponsored mobile apps were detected in Spain.
  • Companies Mentioned: Novo Nordisk, Merck / MSD, Sanofi, AstraZeneca, BoehringerIngelheim, Eli Lilly, J&J / Janssen, Takeda, GSK, Roche, Bayer.

Scope

  • This report analyzes digital activities undertaken by Pharma in support of therapies for Type 2 Diabetes (T2D), with a focus on DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists.
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January - December 2017.

Reasons to buy

  • Our Digital Landscape report provides an analysis of Pharma multichannel activity in the digital T2D space, and can assist our Pharma clients derive value in a number of ways:
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in T2D
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in T2D and beyond, and learn about key patient and physician online activities in T2D.

Table of Contents

  • Executive Summary
  • >Recent Developments
  • Landscape & Analysis
  • US: Patient-directed Activities
  • US HCP-directed Activities
  • EUCAN Patient-directed Activities
  • EUCAN HCP-directed Activities
  • Methodology
Back to Top